ArticleScientific reports2021
Optimization of probiotic therapeutics using machine learning in an artificial human gastrointestinal tract.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Decoding the microbiome: artificial intelligence-targeted gut microenvironment breakthroughs in personalized cancer therapy.Gut microbes · 2026Review
- The Role of Artificial Intelligence and Machine Learning in Revolutionizing Probiotic Research.Microorganisms · 2026Review
- Artificial Intelligence in Food-Nutrition-Health Research: From Multimodal Data Integration to Precision Intervention.Journal of food science · 2026Review
- Functional Foods and Micro- and Nanoplastics: Advances in Precision Nutritional Medicine for Oral-Gut-Brain Axis Health.Antioxidants (Basel, Switzerland) · 2026Review
- Probiotic-Plant Bioactive Synergy in Gut Health: Mechanisms, Antimicrobial Activity, and Translational Challenges.Nutrients · 2026Review
- Probiotics and Postbiotics in Life-Style Disease Management: A Comprehensive Review on the Technologies in the Era of Omics and Artificial Intelligence.Probiotics and antimicrobial proteins · 2026Review
- Bifidobacterium's Influential Role in the Battle Against Obesity: Going Beyond Probiotics.Probiotics and antimicrobial proteins · 2026Review
- Transformer Models, Graph Networks, and Generative AI in Gut Microbiome Research: A Narrative Review.Bioengineering (Basel, Switzerland) · 2026Review
- Biotechnological Approaches to Probiotics and Postbiotics through the Gut-Brain Axis Modulation.Iranian biomedical journal · 2026Article
- Computational and multi-omics systems biology for precision microbiome therapeutics.Frontiers in microbiomes · 2026Review
- Enhanced formulation of precision probiotics through active machine learning.Biology methods & protocols · 2026Article
- Probiotic Potential of Traditional and Emerging Microbial Strains in Functional Foods: From Characterization to Applications and Health Benefits.Microorganisms · 2025Review
- A comprehensive landscape of AI applications in broad-spectrum drug interaction prediction: a systematic review.Journal of cheminformatics · 2025Review
- Probiotic Bacteria as Therapeutics and Biohybrid Drug Carriers: Advances, Design Strategies, and Future Outlook.ACS applied bio materials · 2025Review
- Article
- Next-generation probiotics and engineered BEVs for precision therapeutics in osteoporosis.Frontiers in nutrition · 2025Review
- Neuroinflammation and Schizophrenia: New Therapeutic Strategies through Psychobiotics, Nanotechnology, and Artificial Intelligence (AI).Journal of personalized medicine · 2024Review
- Characterization of the Effects of a Novel Probiotic onAnimals : an open access journal from MDPI · 2024Article
- Machine learning-enhanced assessment of potential probiotics from healthy calves for the treatment of neonatal calf diarrhea.Frontiers in microbiology · 2024Article
- 'Multi-omics' data integration: applications in probiotics studies.NPJ science of food · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The gut microbiota's metabolome is composed of bioactive metabolites that confer disease resilience. Probiotics' therapeutic potential hinges on their metabolome altering ability; however, characterizing probiotics' metabolic activity remains a formidable task. In order to solve this problem, an artificial model of the human gastrointestinal tract is introduced coined the ABIOME (A Bioreactor Imitation of the Microbiota Environment) and used to predict probiotic formulations' metabolic activity and hence therapeutic potential with machine learning tools. The ABIOME is a modular yet dynamic system with real-time monitoring of gastrointestinal conditions that support complex cultures representative of the human microbiota and its metabolome. The fecal-inoculated ABIOME was supplemented with a polyphenol-rich prebiotic and combinations of novel probiotics that altered the output of bioactive metabolites previously shown to invoke anti-inflammatory effects. To dissect the synergistic interactions between exogenous probiotics and the autochthonous microbiota a multivariate adaptive regression splines (MARS) model was implemented towards the development of optimized probiotic combinations with therapeutic benefits. Using this algorithm, several probiotic combinations were identified that stimulated synergistic production of bioavailable metabolites, each with a different therapeutic capacity. Based on these results, the ABIOME in combination with the MARS algorithm could be used to create probiotic formulations with specific therapeutic applications based on their signature metabolic activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.